These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 16854695)

  • 21. [Respiratory syncytial virus prophylaxis among preterm infants--four seasons' experience].
    Klimek M; Kwinta P; Kruczek P; Pietrzyk JJ
    Przegl Lek; 2009; 66(1-2):34-8. PubMed ID: 19485253
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Experience with the use of palivizumab together with infection control measures to prevent respiratory syncytial virus outbreaks in neonatal intensive care units.
    Kurz H; Herbich K; Janata O; Sterniste W; Bauer K
    J Hosp Infect; 2008 Nov; 70(3):246-52. PubMed ID: 18799241
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors impacting compliance with palivizumab prophylaxis.
    Pignotti MS; Indolfi G; Donzelli G
    Pediatr Infect Dis J; 2004 Feb; 23(2):186-7. PubMed ID: 14872196
    [No Abstract]   [Full Text] [Related]  

  • 24. Appropriate prophylaxis with restrictive palivizumab regimen in preterm children in Sweden.
    Navér L; Eriksson M; Ewald U; Linde A; Lindroth M; Schollin J
    Acta Paediatr; 2004 Nov; 93(11):1470-3. PubMed ID: 15513574
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevention of respiratory syncytial virus infection among Puerto Rican infants.
    Winchester L; García L; García I; Concepción CB
    P R Health Sci J; 2002 Sep; 21(3):191-3. PubMed ID: 12243108
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry.
    Frogel M; Nerwen C; Cohen A; VanVeldhuisen P; Harrington M; Boron M;
    J Perinatol; 2008 Jul; 28(7):511-7. PubMed ID: 18368063
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of an interventional program on adherence to the american academy of pediatrics guidelines for palivizumab prophylaxis.
    Afghani B; Ngo T; Leu SY; Wu FL; Cecilio M; Aron-Johnson P; Zeitany R; Sills J; Amin A
    Pediatr Infect Dis J; 2006 Nov; 25(11):1019-24. PubMed ID: 17072124
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Strategies for prevention of RSV nosocomial infection.
    Groothuis J; Bauman J; Malinoski F; Eggleston M
    J Perinatol; 2008 May; 28(5):319-23. PubMed ID: 18368056
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Economic analysis of palivizumab in infants with congenital heart disease.
    Yount LE; Mahle WT
    Pediatrics; 2004 Dec; 114(6):1606-11. PubMed ID: 15574622
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preventing RSV bronchiolitis in vulnerable infants: the role of palivizumab.
    Fitzgerald DA
    Paediatr Respir Rev; 2009 Sep; 10(3):143-7. PubMed ID: 19651385
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Respiratory syncytial virus prophylaxis: a survey of pediatric solid organ transplant centers.
    Michaels MG; Fonseca-Aten M; Green M; Charsha-May D; Friedman B; Seikaly M; Sánchez PJ
    Pediatr Transplant; 2009 Jun; 13(4):451-6. PubMed ID: 18785906
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of palivizumab in Germany: data from 2002-2007.
    Simon A; Nowak H; Sterz R
    Klin Padiatr; 2011 Sep; 223(5):292-8. PubMed ID: 21509705
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Decline in respiratory syncytial virus hospitalizations in a region with high hospitalization rates and prolonged season.
    Singleton RJ; Bruden D; Bulkow LR; Varney G; Butler JC
    Pediatr Infect Dis J; 2006 Dec; 25(12):1116-22. PubMed ID: 17133156
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Respiratory syncytial virus (RSV) loads in premature infants with and without prophylactic RSV fusion protein monoclonal antibody.
    DeVincenzo JP; Aitken J; Harrison L
    J Pediatr; 2003 Jul; 143(1):123-6. PubMed ID: 12915838
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of compliance with palivizumab recommendations in a multicenter study of young children presenting to the emergency department with bronchiolitis.
    Mansbach J; Kunz S; Acholonu U; Clark S; Camargo CA
    Pediatr Emerg Care; 2007 Jun; 23(6):362-7. PubMed ID: 17572518
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants.
    DeVincenzo JP; Hall CB; Kimberlin DW; Sánchez PJ; Rodriguez WJ; Jantausch BA; Corey L; Kahn JS; Englund JA; Suzich JA; Palmer-Hill FJ; Branco L; Johnson S; Patel NK; Piazza FM
    J Infect Dis; 2004 Sep; 190(5):975-8. PubMed ID: 15295704
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of palivizumab to control an outbreak of syncytial respiratory virus in a neonatal intensive care unit.
    Abadesso C; Almeida HI; Virella D; Carreiro MH; Machado MC
    J Hosp Infect; 2004 Sep; 58(1):38-41. PubMed ID: 15350712
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Palivizumab use in very premature infants in the neonatal intensive care unit.
    Wu SY; Bonaparte J; Pyati S
    Pediatrics; 2004 Nov; 114(5):e554-6. PubMed ID: 15520088
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Compliance with prophylaxis for respiratory syncytial virus infection in a home setting.
    Golombek SG; Berning F; Lagamma EF
    Pediatr Infect Dis J; 2004 Apr; 23(4):318-22. PubMed ID: 15071285
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CARESS: the Canadian registry of palivizumab.
    Mitchell I; Paes BA; Li A; Lanctôt KL;
    Pediatr Infect Dis J; 2011 Aug; 30(8):651-5. PubMed ID: 21343842
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.